(FATE) Fate Therapeutics - Ratings and Ratios

Fate Therapeutics, Inc. (NASDAQ:FATE) is a clinical-stage biopharmaceutical company pioneering the development of programmed cellular immunotherapies for the treatment of cancer and immune disorders. Leveraging its proprietary induced pluripotent stem cell (iPSC) platform, the company designs and manufactures off-the-shelf chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. Its pipeline includes FT576, an iPSC-derived CAR NK cell therapy targeting multiple myeloma, and FT522, a CAR T-cell product candidate for lymphoma and autoimmune disorders. Additionally, the company is advancing FT819, a next-generation CAR T-cell therapy for hematologic malignancies and solid tumors, and FT825, a novel CAR T-cell program targeting solid tumors. Fate Therapeutics has established a strategic collaboration and option agreement with Ono Pharmaceutical Co. Ltd. to co-develop and commercialize iPSC-derived CAR T-cell therapies for cancer. Founded in 2007, the company is headquartered in San Diego, California, and has established itself as a leader in the field of cell therapy innovation.

Based on and , the stock is currently trading at $0.95 with a 20-day average volume of 2,979,996 shares. The 20-day SMA is $1.30, while the 50-day SMA is $1.42, and the 200-day SMA is $2.90. The ATR is $0.14. From a perspective, the company has a market cap of $124.14M, a P/B ratio of 0.36, and a P/S ratio of 9.23, with an RoE of -49.19. Over the next three months, the stock is likely to remain under pressure due to the negative earnings and high P/S ratio. However, the low ATR and oversold position relative to the 200-day SMA may support a modest rebound. Expect a sideways to slightly bearish trend, with potential upside limited by the companys current financial position and clinical trial progress.